Ikemura Mai, Hirabatake Masaki, Aburaya Megumi, Ikesue Hiroaki, Yasui Hisateru, Muroi Nobuyuki, Hashida Tohru
Faculty of Pharmaceutical Sciences, Kobe Gakuin University, Kobe, Japan.
Department of Pharmacy, Kobe City Medical Center General Hospital, Kobe, Japan.
Cancer Diagn Progn. 2025 Jan 3;5(1):42-48. doi: 10.21873/cdp.10410. eCollection 2025 Jan-Feb.
BACKGROUND/AIM: The high mortality rate associated with colon cancer in patients with diabetes is well-established; however, the underlying mechanisms have not been fully elucidated. Here, we investigated the efficacy of modified FOLFOX6 (mFOLFOX6) therapy, which is frequently used in colon cancer treatment, in patients with and without comorbid diabetes.
The participants in this retrospective cohort study received mFOLFOX6 therapy as a first-line treatment for incurable/ unresectable and advanced/recurrent colon cancer. We compared patient background characteristics; number of mFOLFOX6 courses; total dose of each drug; reasons for dose reduction, deferment, or discontinuation; and survival time.
Data of six patients with diabetes and 26 without diabetes were assessed. There was no significant difference in background characteristics between the patient groups, with the exception of blood glucose levels. There was no significant difference in the planned number of mFOLFOX6 courses between the groups; however, the total number of completed courses was significantly lower in patients with diabetes than in those without diabetes. Discontinuation rates due to adverse events were similar between the groups; however, discontinuation due to progressive disease or death was significantly higher in patients with diabetes than in those without diabetes. No significant differences were observed in the total dose of each anticancer drug or survival time between the groups.
mFOLFOX6 may not have sufficient therapeutic effects in patients with diabetes. Therefore, in patients with concurrent diabetes and colon cancer, alternative therapeutic options for cancer treatment should be considered.
背景/目的：糖尿病患者结肠癌相关的高死亡率已得到充分证实；然而，其潜在机制尚未完全阐明。在此，我们研究了常用于结肠癌治疗的改良FOLFOX6（mFOLFOX6）疗法对合并和未合并糖尿病患者的疗效。
本回顾性队列研究的参与者接受mFOLFOX6疗法作为不可治愈/不可切除及晚期/复发性结肠癌的一线治疗。我们比较了患者的背景特征；mFOLFOX6疗程数；每种药物的总剂量；剂量减少、延迟或停药的原因；以及生存时间。
评估了6例糖尿病患者和26例非糖尿病患者的数据。除血糖水平外，患者组间背景特征无显著差异。两组间计划的mFOLFOX6疗程数无显著差异；然而，糖尿病患者完成的疗程总数显著低于非糖尿病患者。两组因不良事件导致的停药率相似；然而，糖尿病患者因疾病进展或死亡导致的停药率显著高于非糖尿病患者。两组间每种抗癌药物的总剂量或生存时间均未观察到显著差异。
mFOLFOX6对糖尿病患者可能没有足够的治疗效果。因此，对于合并糖尿病和结肠癌的患者，应考虑其他癌症治疗选择。
